Madrigal Pharmaceuticals (MDGL) 10-Q2017 Q1 Quarterly report

Filed: 11 May 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: attached, Document, furnished, gave, Index, irrespective, judgment, language, Linkbase, recapitalization, retroactively, Schema, supplement, Taxonomy, thereunto, thousand, undersigned, XBRL

Removed: accreted, achieve, achievement, acquire, acting, administered, adversely, advisory, announced, annually, anticipate, approved, chemical, collaboration, combination, combining, commercialize, commercialized, committed, complex, concluded, consisting, consolidation, continued, create, customer, dated, decreased, defending, define, demonstrate, demonstrated, depend, dependent, detailed, determining, disclose, discovery, doubt, earliest, employed, ending, enforcing, enrolled, enrollment, entity, entry, estimated, European, existing, extent, favorable, FDA, fee, final, finance, foreign, fully, generate, greater, guarantee, historically, history, human, identify, identifying, important, improvement, improving, increasing, IND, independently, initial, inside, institution, insufficient, intellectual, intended, involved, issuing, lack, lease, lender, licensing, life, litigation, lower, maintenance, manner, mechanism, modified, office, order, outcome, participation, patient, percentage, permit, person, portion, predictive, priority, profit, prolonged, promote, property, proposed, prosecuting, prosecution, prospectively, pursuing, qualified, Rebecca, recent, reduce, refer, referred, reform, reimbursed, relinquish, rely, render, Reorganization, require, requirement, requisite, responsibility, revenue, review, secured, seek, selling, shown, small, solid, strategy, submission, submitting, substance, successfully, supply, supporting, target, targeted, targeting, Taub, team, term, terminate, termination, therapy, treated, twelve, unable, upfront, variety, vesting, wide, widely

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

MDGL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350)), each of the undersigned officers of Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2017 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 11, 2017		/s/ Paul A. Friedman, M.D.
		Paul A. Friedman, M.D.
		Chief Executive Officer and Chairman of the Board
		(Principal Executive Officer)


Dated: May 11, 2017		/s/ Marc R. Schneebaum
		Marc R. Schneebaum
		Senior Vice President and Chief Financial Officer
		(Principal Accounting and Financial Officer)

These certifications accompany the Form 10-Q, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.